Michael E Nassif1,2, Mohammed Qintar1,2, Sheryl L Windsor1, Rita Jermyn3, David M Shavelle4, Fengming Tang1, Sumant Lamba5, Kunjan Bhatt6, John Brush7,8, Andrew Civitello9, Robert Gordon10, Orvar Jonsson11, Brent Lampert12, Jamie Pelzel13, Mikhail N Kosiborod1,2,14,15. 1. Saint Luke's Mid America Heart Institute, Kansas City, MO (M.E.N., M.Q., S.L.W., F.T., M.N.K.). 2. University of Missouri-Kansas City (M.E.N., M.Q., M.N.K.). 3. St. Francis, Roslyn, NY (R.J.). 4. University of Southern California, Los Angeles (D.M.S.). 5. First Coast Cardiovascular Institute, Jacksonville, FL (S.L.). 6. Austin Heart, TX (K.B.). 7. Sentara Healthcare, Norfolk, VA (J.B.). 8. Eastern Virginia Medical School, Norfolk (J.B.). 9. Baylor College of Medicine, Houston, TX (A.C.). 10. NorthShore University HealthSystem, Evanston, IL (R.G.). 11. University of South Dakota Sanford Health, Sioux Falls (O.J.). 12. The Ohio State University, Columbus (B.L.). 13. Saint Cloud Hospital CentraCare Heart and Vascular Center, MN (J.P.). 14. The George Institute for Global Health, Sydney, Australia (M.N.K.). 15. University of New South Wales, Sydney, Australia (M.N.K.).
Abstract
BACKGROUND: Sodium glucose cotransporter 2 inhibitors (SGLT2 inhibitors) prevent heart failure (HF) hospitalizations in patients with type 2 diabetes and improve outcomes in those with HF and reduced ejection fraction, regardless of type 2 diabetes. Mechanisms of HF benefits remain unclear, and the effects of SGLT2 inhibitor on hemodynamics (filling pressures) are not known. The EMBRACE-HF trial (Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure) was designed to address this knowledge gap. METHODS: EMBRACE-HF is an investigator-initiated, randomized, multicenter, double-blind, placebo-controlled trial. From July 2017 to November 2019, patients with HF (regardless of ejection fraction, with or without type 2 diabetes) and previously implanted pulmonary artery (PA) pressure sensor (CardioMEMS) were randomized across 10 US centers to empagliflozin 10 mg daily or placebo and treated for 12 weeks. The primary end point was change in PA diastolic pressure (PADP) from baseline to end of treatment (average PADP weeks 8-12). Secondary end points included health status (Kansas City Cardiomyopathy Questionnaire score), natriuretic peptides, and 6-min walking distance. RESULTS: Overall, 93 patients were screened, and 65 were randomized (33 to empagliflozin, 32 to placebo). The mean age was 66 years; 63% were male; 52% had type 2 diabetes; 54% were in New York Heart Association class III/IV; mean ejection fraction was 44%; median NT-proBNP (N-terminal pro B-type natriuretic peptide) was 637 pg/mL; and mean PADP was 22 mm Hg. Empagliflozin significantly reduced PADP, with effects that began at week 1 and amplified over time; average PADP (weeks 8-12) was 1.5 mm Hg lower (95% CI, 0.2-2.8; P=0.02); and at week 12, PADP was 1.7 mm Hg lower (95% CI, 0.3-3.2; P=0.02) with empagliflozin versus placebo. Results were consistent for PA systolic and PA mean pressures. There was no difference in mean loop diuretic management (daily furosemide equivalents) between treatment groups. No significant differences between treatment groups were observed in Kansas City Cardiomyopathy Questionnaire scores, natriuretic peptide levels, and 6-min walking distance. CONCLUSIONS: In patients with HF and CardioMEMS PA pressure sensor, empagliflozin produced rapid reductions in PA pressures that were amplified over time and appeared to be independent of loop diuretic management. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03030222.
BACKGROUND: Sodium glucose cotransporter 2 inhibitors (SGLT2 inhibitors) prevent heart failure (HF) hospitalizations in patients with type 2 diabetes and improve outcomes in those with HF and reduced ejection fraction, regardless of type 2 diabetes. Mechanisms of HF benefits remain unclear, and the effects of SGLT2 inhibitor on hemodynamics (filling pressures) are not known. The EMBRACE-HF trial (Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure) was designed to address this knowledge gap. METHODS: EMBRACE-HF is an investigator-initiated, randomized, multicenter, double-blind, placebo-controlled trial. From July 2017 to November 2019, patients with HF (regardless of ejection fraction, with or without type 2 diabetes) and previously implanted pulmonary artery (PA) pressure sensor (CardioMEMS) were randomized across 10 US centers to empagliflozin 10 mg daily or placebo and treated for 12 weeks. The primary end point was change in PA diastolic pressure (PADP) from baseline to end of treatment (average PADP weeks 8-12). Secondary end points included health status (Kansas City Cardiomyopathy Questionnaire score), natriuretic peptides, and 6-min walking distance. RESULTS: Overall, 93 patients were screened, and 65 were randomized (33 to empagliflozin, 32 to placebo). The mean age was 66 years; 63% were male; 52% had type 2 diabetes; 54% were in New York Heart Association class III/IV; mean ejection fraction was 44%; median NT-proBNP (N-terminal pro B-type natriuretic peptide) was 637 pg/mL; and mean PADP was 22 mm Hg. Empagliflozin significantly reduced PADP, with effects that began at week 1 and amplified over time; average PADP (weeks 8-12) was 1.5 mm Hg lower (95% CI, 0.2-2.8; P=0.02); and at week 12, PADP was 1.7 mm Hg lower (95% CI, 0.3-3.2; P=0.02) with empagliflozin versus placebo. Results were consistent for PA systolic and PA mean pressures. There was no difference in mean loop diuretic management (daily furosemide equivalents) between treatment groups. No significant differences between treatment groups were observed in Kansas City Cardiomyopathy Questionnaire scores, natriuretic peptide levels, and 6-min walking distance. CONCLUSIONS: In patients with HF and CardioMEMS PA pressure sensor, empagliflozin produced rapid reductions in PA pressures that were amplified over time and appeared to be independent of loop diuretic management. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03030222.
Authors: Husam M Salah; Subodh Verma; Carlos G Santos-Gallego; Ankeet S Bhatt; Muthiah Vaduganathan; Muhammad Shahzeb Khan; Renato D Lopes; Subhi J Al'Aref; Darren K McGuire; Marat Fudim Journal: J Cardiovasc Transl Res Date: 2022-03-15 Impact factor: 4.132
Authors: Muthiah Vaduganathan; Brian L Claggett; Pardeep Jhund; Rudolf A de Boer; Adrian F Hernandez; Silvio E Inzucchi; Mikhail N Kosiborod; Carolyn S P Lam; Felipe Martinez; Sanjiv J Shah; Akshay S Desai; Sheila M Hegde; Daniel Lindholm; Magnus Petersson; Anna Maria Langkilde; John J V McMurray; Scott D Solomon Journal: JAMA Cardiol Date: 2022-10-03 Impact factor: 30.154
Authors: Chad M Kosanovich; Hongyang Pi; Adam Handen; Erin Schikowski; Yimin Chen; Floyd W Thoma; Suresh Mulukutla; Steve Koscumb; Mehdi Nouraie; Stephen Y Chan Journal: Pulm Circ Date: 2022-06-07 Impact factor: 2.886
Authors: Randa Abdelmasih; Ramy Abdelmaseih; Ravi Thakker; Mohammed Faluk; Arroj Ali; M Mrhaf Alsamman; Syed Mustajab Hasan Journal: Cardiol Res Date: 2021-06-05
Authors: Taijyu Satoh; Longfei Wang; Cristina Espinosa-Diez; Bing Wang; Scott A Hahn; Kentaro Noda; Elizabeth R Rochon; Matthew R Dent; Andrea R Levine; Jeffrey J Baust; Samuel Wyman; Yijen L Wu; Georgios A Triantafyllou; Ying Tang; Mike Reynolds; Sruti Shiva; Cynthia St Hilaire; Delphine Gomez; Dmitry A Goncharov; Elena A Goncharova; Stephen Y Chan; Adam C Straub; Yen-Chun Lai; Charles F McTiernan; Mark T Gladwin Journal: Circulation Date: 2021-06-23 Impact factor: 39.918